In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Journal title
Antimicrobial agents and chemotherapyDate Published
1999-09Publication Volume
43Publication Issue
9Publication Begin page
2268Publication End page
72
Metadata
Show full item recordAbstract
Chlamydia pneumoniae is a well-established cause of community-acquired pneumonia and bronchitis in adults and children. Chronic infections with C. pneumoniae have been implicated in the development of atherosclerosis and other diseases in humans. Methods currently used for the culture and propagation of C. pneumoniae are not analogous to the infection as it occurs in vivo. We have established a model of continuous C. pneumoniae infection in vitro. HEp-2 cells inoculated with CM-1 and TW-183 strains have been persistently infected for periods of over 1.5 and 2 years, respectively. The cultures were maintained without centrifugation or the addition of cycloheximide, fresh host cells, or chlamydia. We observed cycles of host cell lysis, detachment, and regrowth with both strains of C. pneumoniae. Continuous C. pneumoniae infections may more closely resemble the actual events as they occur in vivo and, therefore, may be a better model for the in vitro study of C. pneumoniae infection. When we used continuously infected cells to determine the effects of azithromycin and ofloxacin on C. pneumoniae propagation in vitro, we found that both drugs reduced but did not completely eliminate the organism. This may be an important observation, as the failure of antibiotic therapy against C. pneumoniae infection in humans has been described.Citation
Kutlin A, Roblin PM, Hammerschlag MR. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model. Antimicrob Agents Chemother. 1999 Sep;43(9):2268-72. doi: 10.1128/AAC.43.9.2268. PMID: 10471577; PMCID: PMC89459.Collections
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International
Related articles
- Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.
- Authors: Kutlin A, Roblin PM, Hammerschlag MR
- Issue date: 2002 Feb
- In vitro activity of trovafloxacin against Chlamydia pneumoniae.
- Authors: Roblin PM, Kutlin A, Hammerschlag MR
- Issue date: 1997 Sep
- In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae.
- Authors: Hammerschlag MR, Qumei KK, Roblin PM
- Issue date: 1992 Jul
- The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae.
- Authors: Hammerschlag MR, Roblin PM
- Issue date: 2004 Jul
- Effect of gemifloxacin on viability of Chlamydia pneumoniae (Chlamydophila pneumoniae) in an in vitro continuous infection model.
- Authors: Kutlin A, Roblin PM, Hammerschlag MR
- Issue date: 2002 May